[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605363":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":33,"locations":39,"responsibleParty":157,"collaborators":159,"id":163,"slug":32,"hasResults":164,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":164,"sex":170,"minAge":171,"maxAge":172,"enrollmentInfo":173,"targetDuration":32,"studyType":176,"phases":177,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":42,"whyStopped":32,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":196},{"fullName":5,"class":6},"AAVantgarde Bio Srl","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","AAVB-039 dose level 1 (low dose)",[13],"Biological: AAVB-039",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2","AAVB-039 dose level 2 (mid dose)",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3","AAVB-039 dose level 3 (high dose)",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Cohorts 4-5","AAVB-039 dose level 1, 2 or 3",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"BIOLOGICAL","AAVB-039","Single subretinal administration",[9,15,19,23],null,[34],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"AAVantgarde Clinical Operations Lead","CONTACT","+448000465680","clinicaltrials@aavantgarde.com",[40,60,79,96,109,124,140,151],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Associated Retina Consultants","RECRUITING","Phoenix","Arizona","85020","United States",{"type":48,"coordinates":49},"Point",[50,51],-112.07404,33.44838,{"lat":51,"lon":50},[54,57],{"name":55,"role":36,"phone":32,"phoneExt":32,"email":56},"Study Team","hello@doctrials.com",{"name":58,"role":59,"phone":32,"phoneExt":32,"email":32},"Benjamin Bakall","PRINCIPAL_INVESTIGATOR",{"facility":61,"status":42,"city":62,"state":63,"zip":64,"country":46,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Retina Vitreous Associates Medical Group","Los Angeles","California","90211",{"type":48,"coordinates":66},[67,68],-118.24368,34.05223,{"lat":68,"lon":67},[71,74,77],{"name":72,"role":36,"phone":32,"phoneExt":32,"email":73},"Kristina Passoian, Trials Director","Kpassoian@laretina.com",{"name":75,"role":36,"phone":32,"phoneExt":32,"email":76},"Study Referrals","Studyreferrals@laretina.com",{"name":78,"role":59,"phone":32,"phoneExt":32,"email":32},"David Liao",{"facility":80,"status":42,"city":81,"state":82,"zip":83,"country":46,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Mayo Clinic","Rochester","Minnesota","55905",{"type":48,"coordinates":85},[86,87],-92.4699,44.02163,{"lat":87,"lon":86},[90,94],{"name":91,"role":36,"phone":92,"phoneExt":32,"email":93},"Suzy Wernimont","507-538-8119","Wernimont.Suzanne@mayo.edu",{"name":95,"role":59,"phone":32,"phoneExt":32,"email":32},"Brittni Scruggs",{"facility":97,"status":42,"city":98,"state":99,"zip":100,"country":46,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Retina Consultants of Texas","Bellaire","Texas","77401",{"type":48,"coordinates":102},[103,104],-95.45883,29.70579,{"lat":104,"lon":103},[107],{"name":108,"role":59,"phone":32,"phoneExt":32,"email":32},"Kenneth Fan",{"facility":110,"status":42,"city":111,"state":99,"zip":112,"country":46,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Retina Foundation of the Southwest","Dallas","75231",{"type":48,"coordinates":114},[115,116],-96.80667,32.78306,{"lat":116,"lon":115},[119,122],{"name":120,"role":36,"phone":32,"phoneExt":32,"email":121},"Senior Clinical Research Coordinator","jclark@retinafoundation.org",{"name":123,"role":59,"phone":32,"phoneExt":32,"email":32},"Karl Csaky",{"facility":125,"status":42,"city":126,"state":127,"zip":128,"country":46,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"University of Utah","Salt Lake City","Utah","84112",{"type":48,"coordinates":130},[131,132],-111.89105,40.76078,{"lat":132,"lon":131},[135,138],{"name":136,"role":36,"phone":32,"phoneExt":32,"email":137},"Kimberley Wegner Lead Coordinator","Kimberley.wegner@hsc.utah.edu",{"name":139,"role":59,"phone":32,"phoneExt":32,"email":32},"Paul Bernstein",{"facility":141,"status":42,"city":142,"state":143,"zip":144,"country":145,"cosmosGeoPoint":146,"geoPoint":150,"contacts":32},"Moorfields Eye Hospital NHS Foundation Trust","London","England","EC1V 2PD","United Kingdom",{"type":48,"coordinates":147},[148,149],-0.12574,51.50853,{"lat":149,"lon":148},{"facility":152,"status":42,"city":142,"state":143,"zip":153,"country":145,"cosmosGeoPoint":154,"geoPoint":156,"contacts":32},"The Retina Clinic","W1G 9AX",{"type":48,"coordinates":155},[148,149],{"lat":149,"lon":148},{"type":158,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[160],{"name":161,"class":162},"AAVantgarde Bio UK Ltd","UNKNOWN","100605363",false,"NCT07161544","A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)","An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants With Stargardt Disease (STGD1) (CELESTE)","CELESTE","Inclusion Criteria:\n\n* Molecular diagnosis of Stargardt disease due to ABCA4 mutation\n* Willingness to adhere to protocol per informed consent\n\nExclusion Criteria:\n\n* Unwillingness to meet the requirements of the study\n* Participation in a clinical study with another Investigation Medicinal Product\n* Previous participation in another gene or cell therapy trial\n* Any condition that would preclude subretinal surgery\n* Complicating ocular and\u002For systemic diseases","ALL","8 Years","55 Years",{"count":174,"type":175},75,"ESTIMATED","INTERVENTIONAL",[178,179],"PHASE1","PHASE2","The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the ABCA4 gene. The study will also assess initial efficacy following AAVB-039 administration.",[182],"Stargardt Disease",[182,184,185,186],"Biallelic Mutation","Gene Mutation","ABCA4","2026-06-19",{"date":189,"type":190},"2026-06-23","ACTUAL",{"date":192,"type":190},"2025-09-29",{"date":194,"type":175},"2032-07",{"name":5,"class":6},8]